Selective serotonin reuptake inhibitors (SSRIs) including sertraline (Zoloft) have been found to be effective in the treatment of generalized social phobia (GSP). However, virtually all of the current treatment studies with medicines, including the SSRIs, have excluded patients with social phobia who have other co-occurring conditions. In fact, 80% of individuals suffering with primary social phobia have at least one other anxiety. This study will evaluate the safety and efficacy of sertraline in the treatment of generalized social phobia with co-occurring anxiety and mood disorders. Participants will be randomized to receive either sertraline or placebo for 16 weeks. At the end of the study, you will enter follow-up care with the study doctor.

McMaster University Medical Centre
Principal Investigator
Michael Van Ameringen, MD
Eligibility Criteria
  • Male or female outpatients 18 years or older with a primary diagnosis of generalized social anxiety disorder as well as at least one another anxiety disorder (as determined by the psychiatrists who conduct our initial screening process).
  • Physical examination, electrocardiogram, and laboratory findings without clinically significant abnormalities.
  • Willingness and ability to comply with the requirements of the study protocol.
  • Those taking other psychotrophic medications are excluded.
The MacAnxiety Research Centre, 905-921-7644 or e-mail
Hamilton, ON